Location Trial Status:

= Fully recruited

= Recruiting

= Not yet recruiting

= Enrolling by invitation

Wave Life Sciences Exon 51

A Multicentre, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy

Hub Summary

This phase 1 study is designed to determine the safety and tolerability of Wave Life Science’s Exon 51 skipping therapy.

Study Number: NCT03508947

Description by Wave Life Sciences

This is a Phase 1, double-blind, placebo-controlled, single ascending dose cohort study to evaluate the safety, tolerability, and plasma concentrations of WVE-210201 in ambulatory and non-ambulatory male paediatric patients with DMD amenable to exon 51 skipping intervention.

Primary Outcome Measures

  • Number of patients with adverse events (AEs)
  • Severity of AEs
  • Number of patients with serious AEs (SAEs) 
  • Number of patients who withdraw due to AE

Secondary Outcome Measures

  • Maximum observed concentration (Cmax)
  • Time of occurrence of Cmax (tmax)
  • Area under the plasma concentration-time curve (AUC 0-t)

Can I take part?

Inclusion Criteria

  • Diagnosis of Duchenne muscular dystrophy (DMD) based on clinical phenotype with increased serum creatine kinase
  • Documented mutation in the Dystrophin gene associated with DMD that is amenable to exon 51 skipping
  • Ambulatory or non-ambulatory male patients aged ≥5 - ≤18 years
  • Stable pulmonary and cardiac function as measured by: a) reproducible percent predicted forced vital capacity (FVC) ≥50% and b) left ventricular ejection fraction (LVEF) >55% in patients <10 years of age and >45% in patients ≥10 years of age, as measured (and documented) by echocardiogram within one year prior to enrolment into the study.

Exclusion Criteria

  • Severe cardiomyopathy; cardiomyopathy that is managed by angiotensin-converting enzyme (ACE) inhibitors or beta blockers is acceptable provided the patient meets the LVEF inclusion criteria.
  • Need for mechanical or non-invasive ventilation OR anticipated need for mechanical or non-invasive ventilation within the next year, in the opinion of the Investigator.
  • Changes in nutritional or herbal supplements or concomitant medications within 1 month prior to Screening visit or plans to modify dose or regimen during the study.
  • Currently on anticoagulants or antithrombotics.
  • Received treatment with eteplirsen or ataluren within the past 14 weeks.
  • Received prior treatment with drisapersen.
  • Received any investigational drug within the past 3 months or 5 half-lives, whichever is longer.
Download PDF
Overall Trial Status
Fully recruited
Trial Sponsor
Wave Life Sciences
5 to 18 years
Mutation Specific
Mutation specific therapies, must be amenable to exon 51 skipping
Muscle Biopsy
No Muscle Biopsy Required
Recruitment Target
Ambulant and non-ambulant
Therapeutic Category
Exon skipping